Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellProtect plus Isatuximab vs Isatuximab alone as maintenance after high-dose therapy in transplant-eligible newly diagnosed multiple myeloma
2020-000994-26Phase 2Active
- Sponsor
- Karolinska Institutet
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Isatuximab maintenance with Isatuximab + CellProtect maintenance (2 arms). Primary endpoint: Overall response rate after start of maintenance. Started Jul 2020; status: active.
02
Drugs
isatuximabCellProtect
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-000994-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000994-26.